Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2016-06-08 |
Merck Ventures (Germany) |
€ 150 million |
investment - financing round |
Merck KGaA (Germany) |
|
Financing round |
2016-06-08 |
Lion Biotechnologies (USA - CA) |
$100 million |
private placement |
institutional and other accredited investors |
Cancer - Oncology |
Private placement |
2016-06-08 |
Pieris (Germany) |
$16.5 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-06-06 |
Vedanta Biosciences (USA - MA) |
$50 million |
financing round |
Health For Life Capital (Seventure) (France) Invesco Asset Management (UK) PureTech (USA - MA) Rock Springs Capital (USA - MD) |
Autoimmune diseases - Infectious diseases |
Financing round |
2016-06-02 |
LSP (Life Sciences Partners) (The Netherlands) |
$280 million (€250,2 million) |
financing round |
|
|
Financing round |
2016-06-02 |
Miragen Therapeutics (USA - CO) |
up to $424,725 |
grant |
ALS association (USA -DC) |
Neurodegenerative diseases |
Grant |
2016-06-01 |
Ablynx (Belgium) |
€ 74.2 million |
private placement |
|
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases |
Private placement |
2016-05-26 |
Prometic Life Sciences (Canada) |
$ 60 million |
private placement |
|
|
Private placement |
2016-05-24 |
CEL-SCI Corporation (USA -VA) |
$ 5 million |
private placement |
undisclosed single healthcare dedicated institutional investor |
Cancer - Oncology |
Private placement |
2016-05-17 |
Nouscom (Switzerland) |
€ 12 million |
series A financing round |
LSP (The Netherlands) Versant Ventures (USA - CA) |
Cancer - Oncology |
Series A financing round |
2016-05-09 |
AC Immune (Switzerland) |
CHF 42.7 million (€ 38.64 million) |
series E financing round |
undisclosed institutions and existing shareholders |
Neurological diseases - CNS diseases |
Financing round |
2016-05-05 |
|
|
|
|
|
Financing round |
2016-05-05 |
Genvec (USA - MD) |
$5 million (€ 4.38 million) |
private placement |
|
|
Private placement |
2016-05-05 |
Redhill Biopharma (Israel) Medical University of South Carolina (MUSC) (USA - SC) |
$1.8 million |
grant |
National Cancer Institute (NCI) (USA) |
Cancer - Oncology |
Establishment of a new subsidiary in the EU |
2016-05-04 |
Poxel (France) |
|
IPO |
|
Metabolic diseases |
IPO |
2016-05-03 |
Orchard Therapeutics (UK) |
series A financing round |
£21 million (€ 26.52 million) |
F-Prime Capital (USA - MA) UCL Business (UK) UCL Technology Fund (UK) |
Rare diseases - Genetic diseases - Hematological diseases - Immunological diseases - Metabolic diseases |
Series A financing round |
2016-05-03 |
Ideaya Bioscience (USA - CA) |
$46 million |
series A financing round |
5AM Ventures (USA - CA) Canaan Partners (USA - CA) Celgene (USA - NJ) WuXi Healthcare Ventures (China) Novartis Institute of Biomedical Research -Alexandria Real Estate |
Cancer - Oncology |
Series A financing round |
2016-05-02 |
Acadia Pharmaceuticals (USA - CA) |
$300 million |
|
|
|
Private placement |
2016-04-20 |
Enterome Bioscience (France) |
€14.5 million |
series C financing round |
Seventure (France) Lundbeckfond Venture (Denmark) Nestlé Health Science (Switzerland) |
Digestive diseases - Gastrointestinal diseases - Inflammatory diseases |
Series C financing round |
2016-04-20 |
PeptiMimesis (France) |
€1.2 million ($1.4 million) |
financing round |
Cap Innov’Est (France) |
Autoimmune diseases - Cancer - Oncology |
Financing round |